RecruitingPhase 4NCT04046497

Artificial Intelligence to Measure Adherence to Oral Medication

Early-phase Schizophrenia: Practice-based Research to Improve Outcomes (ESPRITO) - Using Artificial Intelligence to Measure Adherence to Oral Medication

Sponsor

Northwell Health

Enrollment

200 participants

Start Date

Nov 20, 2020

Study Type

INTERVENTIONAL

Conditions

First-episode Psychosis

Summary

The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.

Eligibility

Min Age: 15 YearsMax Age: 40 Years

Inclusion Criteria2

Enrolled in a CSC program
Prescribed an oral antipsychotic

Exclusion Criteria1

none

Interventions

OTHERSmartphone App

artificial intelligence (AI) smartphone app to provide support for medication adherence

OTHERUsual Care

Usual Care provided by CSC clinic

Locations(5)

Citrus Health

Hialeah, Florida, United States

InterAct

Grand Rapids, Michigan, United States

InterAct of Michigan

Kalamazoo, Michigan, United States

Red Rock

Oklahoma City, Oklahoma, United States

Family and Children's Services

Tulsa, Oklahoma, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04046497

Related Trials

Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis

NCT043680391 location

Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode

NCT053843926 locations

Digital Strategies to Advance Help-Seeking Aim 1 and 2

NCT067744301 location

Early-Phase Schizophrenia: Practice-based Research to Improve Outcomes

NCT040043641 location